Clinical Characteristics and Response to Newer Quinolones in Legionella Pneumonia: A Report of 28 Cases

REFERENCES

• Tsakris A, Alexiou-Daniel S, Souliou E, Antoniadis A. In-vitro activity of antibiotics against Legionella pneumophila isolates from water systems. J Antimicrob Chemother 1999; 44 (5): 693–5.
   PubMed Web of Science ®Google Scholar
• Edelstein PH. Antimicrobial chemotherapy for Legion-naires' disease: a review. Clin Infect Dis 1995; 21 Suppl 3: S265–76.
   PubMedGoogle Scholar
• Edelstein PH, Edelstein MA, Ren J, Polzer R, Gladue RP. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996; 40 (2): 314-19.
   Google Scholar
• Ruckdeschel G, Dalhoff A. The in-vitro activity of moxi-floxacin against Legionella species and the effects of medium on susceptibility test results. J Antimicrob Chemother 1999; 43 Suppl B: 25-9.
   Google Scholar
• Yu VL. Legionella pneumophila (Legionnaire' disease). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone; 2000: 2424-2435.
   Google Scholar
• England AC, 3rd, Fraser DW, Plikaytis BD, Tsai TF, Storch G, Broome CV. Sporadic legionellosis in the United States: the first thousand cases. Ann Intern Med 1981; 94 (2): 164–70.
   PubMed Web of Science ®Google Scholar
• Plouffe JF. Importance of atypical pathogens of commu-nity-acquired pneumonia. Clin Infect Dis 2000; 31 Suppl 2: S35–9.
   PubMed Web of Science ®Google Scholar
• Lieberman D, Schlaeffer F, Boldur I, Horowitz S, Friedman MG, Leiononen M, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51 (2): 179–84.
   PubMed Web of Science ®Google Scholar
• Baquero F, Garcia-Rodriguez JA, Garcia de Lomas J, Aguilar L. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infec-tions in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999; 43 (2): 357-9.
   Google Scholar
• Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS, et al. In: Beam TRJr., Gilbert DN, Kunin CM, Party EW, editors. General guidelines for the eval-uation of new antiinfective drugs for the treatment of respiratory tract infections: European Society of Clinical Microbiology and Infectious Diseases; 1993: 81-111.
   Google Scholar
• Dedicoat M, Venkatesan P. The treatment of Legionnaires' disease. J Antimicrob Chemother 1999; 43 (6): 747–52.
   PubMed Web of Science ®Google Scholar
• Bernander S, Gastrin B, Lofgren S, Olinder-Nielsen AM. Legionella urinary antigen in early disease. Scand J Infect Dis 1994; 26 (6): 777–8.
   PubMed Web of Science ®Google Scholar
• File TM, Jr., Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study compar-ing the efficacy and safety of intravenous and/or oral lev-ofloxacin versus ceftriaxone and/or cefuroxime axetil in treat-ment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41 (9): 1965–72.
   PubMed Web of Science ®Google Scholar
• Plouffe JF, Herbert MT, File TM, Jr., Baird I, Parsons JN, Kahn JB, et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospi-talization. Pneumonia Study Group. Antimicrob Agents Chemother 1996; 40 (5): 1175–9.
   PubMed Web of Science ®Google Scholar
• Monforte R, Estruch R, Vidal J, Mensa J, Marco F, Cervera R, et al. [A community outbreak of Legionnaires' dis-ease in Barcelona: clinical and microbiological study]. Med Clin (Barc) 1989; 93 (14): 521–5.
   PubMed Web of Science ®Google Scholar
• Lieberman D, Korsonsky I, Ben-Yaakov M, Lazarovich Z, Friedman MG, Dvoskin B, et al. A comparative study of the etiology of adult upper and lower respiratory tract infec-tions in the community. Diagn Microbiol Infect Dis 2002; 42 (1): 21–8.
   PubMed Web of Science ®Google Scholar
• Lehtomaki K, Leinonen M, Takala A, Hovi T, Herva E, Koskela M. Etiological diagnosis of pneumonia in military con-scripts by combined use of bacterial culture and serological methods. Eur J Clin Microbiol Infect Dis 1988; 7 (3): 348–54.
   PubMed Web of Science ®Google Scholar
• Lieberman D, Porath A, Schlaeffer F, Boldur I. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. Chest 1996; 109 (5): 1243-9.
   Google Scholar
• Tan MJ, Tan JS, File TMJr. Legionnaires disease with bacteremic coinfection. Clin Infect Dis 2002; 35 (5): 533–9.
   PubMed Web of Science ®Google Scholar
• Maurin M, Raoult D. Q fever. Clin Microbiol Rev 1999; 12 (4): 518–53.
   PubMed Web of Science ®Google Scholar
• Finidori JP, Raoult D, Bornstein N, Fleurette J. Study of cross-reaction between Coxiella burnetii and Legionella pneumophila using indirect immunofluorescence assay and immunoblotting. Acta Virol 1992; 36 (5): 459–65.
   PubMed Web of Science ®Google Scholar
• Kohler RB, Winn WC, Jr., Wheat II. Onset and dura-tion of urinary antigen excretion in Legionnaires disease. J Clin Microbiol 1984; 20 (4): 605–7.
   PubMed Web of Science ®Google Scholar
• Fields BS, Benson RF, Sesser RE. Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev 2002; 15 (3): 506–26.
   PubMed Web of Science ®Google Scholar
• Dominguez JA, Manterola JM, Blavia R, Sopena N, Belda FJ, Padilla E, et al. Detection of Legionella pneu-mophila serogroup 1 antigen in nonconcentrated urine and urine concentrated by selective ultrafiltration. J Clin Microbiol 1996; 34 (9): 2334–6.
   PubMed Web of Science ®Google Scholar
• Garcia MT, Pelaz C, Gimenez MJ, Aguilar L. In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneu-mophila: influence of charcoal on susceptibility test results. Antimicrob Agents Chemother 2000; 44 (8): 2176–8.
   PubMed Web of Science ®Google Scholar
• Garcia I, Pascual A, Ballesta S, Joyanes P, Perea EJ. Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 2000; 44 (11): 3193–5.
   PubMed Web of Science ®Google Scholar
• Garcia-de-Lomas J, Millas E, Lazaro MA, Bermejo M, Gimeno C, Navarro D, et al. A comparative study on the effi-cacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs. Eur J Clin Microbiol Infect Dis 1998; 17 (6): 420–3.
   PubMed Web of Science ®Google Scholar
• Edelstein PH, Shinzato T, Doyle E, Edelstein MA. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2001; 45 (8): 2204-9.
   Google Scholar